Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...
On the charts, today's pop has NVO on track to snap a three-day losing streak. The stock still hasn't recovered from its mid-December bear gap, after which it hit a Jan. 17, 52-week low of $78.17 amid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback